Upload
Featured Recent Articles Topics Login Upload

Search Results for 'Ldl-Hdl'

Ldl-Hdl published presentations and documents on DocSlides.

Abnormalities of LDL metabolism
Abnormalities of LDL metabolism
by briana-ranney
Physiology, pathophysiology and treatments. Under...
Looking to FOURIER: What do the trials tell us about LDL lowering and cardiovascular events?
Looking to FOURIER: What do the trials tell us about LDL lowering and cardiovascular events?
by min-jolicoeur
NICE –CG 181 Continuum of CVD Risk and its trea...
LDL Apheresis in Drug Resistant Nephrotic Syndrome
LDL Apheresis in Drug Resistant Nephrotic Syndrome
by obrien
Rodney D Gilbert. Patient JM. 14 year old girl, pr...
LDL is causal of atherosclerosis
LDL is causal of atherosclerosis
by morgan
Evidence from . meta-analyses of . Mendelian. . r...
PCSK9 Inhibition: LDL Lowering
PCSK9 Inhibition: LDL Lowering
by SweetiePie
PCSK9 inhibitors. New option for dyslipidemia. Ali...
Lifestyle Tips to Lower Your LDL Cholesterol
Lifestyle Tips to Lower Your LDL Cholesterol
by dandy
Advice f rom the National Lipid Association Clini...
New Insights in
New Insights in
by yoshiko-marsland
the Understanding . of . Cholesterol Metabolism:....
Genetic Variants of Proprotein Convertase Subtilisin/Kexin
Genetic Variants of Proprotein Convertase Subtilisin/Kexin
by mitsue-stanley
Type 9 (PCSK9). Implications for Low-Density Lipo...
The State of
The State of
by olivia-moreira
Dyslipidemia. . Treatment. USA-145-101385. © . ...
Advancing the Understanding
Advancing the Understanding
by briana-ranney
of Cholesterol Metabolism:. The Role of . Proprot...
Familial
Familial
by sherrill-nordquist
Hypercholesterolaemia. . N. ew local pathways. D...
Familial Hypercholesterolemia
Familial Hypercholesterolemia
by faustina-dinatale
KEY POINTS . FH is an autosomal dominant genetic...
Plant stanol ester in the treatment and prevention guidelin
Plant stanol ester in the treatment and prevention guidelin
by stefany-barnette
0. International Atherosclerosis Society, 2013. A...
Protecting the heart and the kidney:
Protecting the heart and the kidney:
by marina-yarberry
Implications from the SHARP trial. Dr. Christina ...
0 Circulation and Gas Exchange
0 Circulation and Gas Exchange
by tatyana-admore
The fluid that moves around in the circulatory sy...
Familial Hypercholesterolemia
Familial Hypercholesterolemia
by pasty-toler
Developed by . Ms. . Shawna . Morrison, Dr. Judit...
Lipid Metabolism
Lipid Metabolism
by kittie-lecroy
Chapter 29, . Stryer. Short Course. Lipid anabol...
Cholesterol Treatment Trialists’ (CTT) Collaboration
Cholesterol Treatment Trialists’ (CTT) Collaboration
by briana-ranney
Slide deck. CTT Collaboration: Background*. Histo...
협심증 ( 狹心症 )
협심증 ( 狹心症 )
by lois-ondreau
Kyung Woo Park, MD, PhD, MBA . Seoul National Uni...
FOURIER F urther cardiovascular
FOURIER F urther cardiovascular
by trish-goza
OU. tcomes. . R. esearch with PCSK9 . I. nhibiti...
Long-term Tolerability and Efficacy of Evolocumab (AMG 145) in
Long-term Tolerability and Efficacy of Evolocumab (AMG 145) in
by pamella-moone
Hyperlipidemic. Subjects: A 52 Week Phase 3 Dou...
HOT TOPICS IN CHOLESTEROL
HOT TOPICS IN CHOLESTEROL
by tatyana-admore
Are Statins as Effective in Women as in Men? Upda...
New developments in lipid management
New developments in lipid management
by pasty-toler
CGR 0800 h 11 May 2015. Rob Hegele MD FRCPC FACP....
Trial Design Evolocumab SC
Trial Design Evolocumab SC
by danika-pritchard
140 mg Q2W or 420 mg QM. Placebo SC. Q2W or QM. L...
LSU Journal Club Efficacy and Safety of
LSU Journal Club Efficacy and Safety of
by trish-goza
Evolocumab. in. Reducing Lipids and Cardiovascul...
PCSK-9 Inhibitors Paul J
PCSK-9 Inhibitors Paul J
by tatyana-admore
PCSK-9 Inhibitors Paul J Kovack , DO, FACC, FACO...
Diabetes and Dyslipidemia
Diabetes and Dyslipidemia
by danika-pritchard
2013 ACC/AHA Guideline on the. Treatment of Blood...
Atherosclerosis By Aravind Kalathil, Sam Eiswirth, and Brooke Turner
Atherosclerosis By Aravind Kalathil, Sam Eiswirth, and Brooke Turner
by myesha-ticknor
Why is Atherosclerosis known as a heart disease?....
HYPERLIPIDAEMIAS Dr.D.Rispa
HYPERLIPIDAEMIAS Dr.D.Rispa
by kaptainpositive
Assistant Professor. Pharmacy Practice Department....
Protecting the heart and the kidney:
Protecting the heart and the kidney:
by pressio
Implications from the SHARP trial. Dr. Christina R...
LDL Cholesterol Lowering with
LDL Cholesterol Lowering with
by shoffer
Evolocumab. and Outcomes in Patients with . Perip...
Oxidized- Low Density Lipoprotein Level Among Organophosphates (OPs)
Oxidized- Low Density Lipoprotein Level Among Organophosphates (OPs)
by mediumgeneral
Pesticide Exposed Workers. Nor Zamzila Abdullah. ...
The New Cholesterol Guidelines:
The New Cholesterol Guidelines:
by lily
Beauty is in the Eye of the Beholder. Brian Asbill...
A naturally randomized trial evaluating the potential clinical benefit of triglyceride lowering the
A naturally randomized trial evaluating the potential clinical benefit of triglyceride lowering the
by arya
Brian A. . Ference. MD, . MPhil. , . MSc. , John ...
DYSLIPIDEMIA IN DIABETES
DYSLIPIDEMIA IN DIABETES
by esther
MAHTAB NIROOMAND M.D.. Assistant professor of End...
Soodeh Razeghi PhD, Assistant professor of nutrition,
Soodeh Razeghi PhD, Assistant professor of nutrition,
by delcy
Shahid. . Beheshti. University of Medical Scienc...
The case for intensive lipid management:
The case for intensive lipid management:
by SillyGoose
The opportunities and issues for cardiologists. Pr...
ODYSSEY FH I and II In FH I:
ODYSSEY FH I and II In FH I:
by Aquamarine
From baseline to 24 weeks, the change in . LDL-C: ...
6701 Carnegie Ave Suite 500 Cleveland OH 44103 p 8663589828
6701 Carnegie Ave Suite 500 Cleveland OH 44103 p 8663589828
by gelbero
ApoE genotype can affect:Response to treatment wit...
THE MANAGEMENT OF DYSLIPIDEMIA Updated Version 20 150 2006
THE MANAGEMENT OF DYSLIPIDEMIA Updated Version 20 150 2006
by ariel
VA/DoD Clinical Practice Guideline Introduction ...